UCSF COVID-19 Rapid Response Pilot Grant

3 Awards

Award Recipient Award date Award Type
The role of tenofovir-based HIV treatment and prevention on COVID-19 prevalence and outcomes Amelia Deitchman, PharmD, PhD Spring UCSF COVID-19 Rapid Response Pilot Grant
Virologic and immunologic correlates of SARS-CoV-2 infection in people living with HIV Michael Peluso, MD, MPhil, MHS Spring UCSF COVID-19 Rapid Response Pilot Grant
Epidemiology, Health Disparities, Public Health HIV Care Engagement and Retention in Care Paul Wesson, PhD Spring UCSF COVID-19 Rapid Response Pilot Grant
Contacts

  • The role of tenofovir-based HIV treatment and prevention on COVID-19 prevalence and outcomes

    The role of tenofovir-based HIV treatment and prevention on COVID-19 prevalence and outcomes

    Abstract

    Little is known regarding risk of COVID-19 in people with HIV (PLWH) and how tenofovir (TFV), an antiretroviral (ART) used for HIV treatment and prevention, may confer protection against COVID-19. This research leverages public health data of PLWH and COVID-19 in San Francisco to determine if HIV itself or ART alters risk of COVID-19 infection.

  • Epidemiology, Health Disparities, Public Health HIV Care Engagement and Retention in Care

    Epidemiology, Health Disparities, Public Health HIV Care Engagement and Retention in Care

    Abstract

    People living with HIV with criminal justice involvement are particularly vulnerable population, with poor pre-release and post-release HIV care cascade outcomes and diverse non-HIV social services engagement. Hence, they are likely to be disproportionately impacted by shelter-in-place orders, reduced incarceration rates and criminal justice reform.

  • Virologic and immunologic correlates of SARS-CoV-2 infection in people living with HIV

    Virologic and immunologic correlates of SARS-CoV-2 infection in people living with HIV

    Abstract

    Little is known about the short- and long-term impact of SARS-CoV-2 infection in people living with HIV. In Aim 1, we will characterize a clinical cohort of People with HIV with PCR-confirmed SARS-CoV-2 through a collaboration with colleagues in New York City. In Aim 2, we will characterize the SARS-CoV-2-specific T cell responses in HIV positive and -negative individuals in the UCSF SCOPE-COVID and LIINC cohorts to determine how these differ in People with HIV. In Aim 3, we will measure the effects of COVID-19 on HIV reservoir dynamics.
Subscribe to UCSF COVID-19 Rapid Response Pilot Grant